Lisata Therapeutics Stock
Lisata Therapeutics, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- David J. Mazzo
- Employees
- 21
- Market cap
- $9 M
- IPO
- 01/03/1999
Lisata Therapeutics, Inc. is a clinical-stage biopharmaceutical firm focused on pioneering and bringing to market cellular therapies. These treatments are designed to either reverse disease progression or facilitate the repair of damaged bodily tissues. The company's product portfolio features several notable…
Lisata Therapeutics stock: price history
1D
-3.7%
1W
-2.8%
1M
-29.9%
6M
-68.1%
YTD
-44.6%
1Y
-59.1%
2Y
-65.0%
5Y
-94.4%
10Y
-98.4%
Next earnings date
Next earnings date
05/11/2026 (in 19 days)
Volatility around earnings
~17% weaker price swings than usual
Ask the agents about Lisata Therapeutics
Analyst assessment of Lisata Therapeutics
0
STRONG BUY
0
BUY
2
HOLD
0
SELL
0
STRONG SELL
2
TOTAL · Hold
As of: 15/05/2026
Lisata Therapeutics stock metrics
P/E
-0.63
P/B
1.14
EV/EBITDA
0.07
RETURN ON EQUITY
-35.5%
NET MARGIN
0.0%
DEBT/EQUITY
0
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
76.0%
FLOAT SHARES
6,848,008
AVG. DAILY VOLUME (30D)
233,146
Institutional holders
Dividends & Stock splits
Dividends
Stock splits
Comparable stocks
Frequently asked questions about Lisata Therapeutics stock
What does Lisata Therapeutics do?
Lisata Therapeutics, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is David J. Mazzo, the company employs around 21 people.
The IPO was on 01/03/1999; the stock trades on NASDAQ under the ticker LSTA.
What do analysts say about Lisata Therapeutics stock?
2 analysts rate the stock, the consensus is Hold (as of 15/05/2026).
This is an external assessment, not a statement by Market Jury.
When does Lisata Therapeutics report next?
The next earnings date is 05/11/2026.
Around past earnings, price swings were roughly -17% stronger than usual.
Does Lisata Therapeutics pay a dividend?
Yes. The last dividend was US$0.00 per share.
The dividend yield is 0.0% (as of 30/06/2026).
Which stocks are comparable to Lisata Therapeutics?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Lisata Therapeutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess Lisata Therapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.